Homepage
Author:
Veloxis Pharmaceuticals, Inc
Posted Date:
May 7, 2026
Pegrizeprument Granted Orphan Drug Designation for Prevention of Organ Rejection in Heart Transplant Patients
Veloxis Pharmaceuticals, Inc
May 7, 2026
Calliditas Therapeutics AB to Present Exploratory Biomarker and Post-Hoc NefIgArd Analyses at the World Congress of Nephrology
Veloxis Pharmaceuticals, Inc
May 4, 2026
